Abstract | INTRODUCTION: MATERIALS AND METHODS: A prospective randomized control trial study enrolled the 212 hyperlipidemia with osteopenia patients to study in year 2006-2008. All subjects were randomized to 2 groups between statin and non- statin group; the patients were screened by inclusion criteria and measured in bone mineral density (BMD), bone marker and blood chemistry. All data were analyzed by difference of changing in bone marker and BMD between statin and non- statin groups using paired t test. RESULTS: The present study showed 212 hyperlipidemia with osteopenia patients of which 106 patients in statin group had mean age (63.17+/-9.51 years) and the same number of patients in non- statin group had mean age (60.96+/-8.9 years). All subjects were 63 patients in male and 149 patients in female. Difference of bone formation marker and BMD between after and before was significantly higher than in statin group and the difference of bone resorption marker was also significantly lower than in statin group. CONCLUSION: The lipophilic statin as moderate to high dose of simvastatin had beneficial positive effect to increasing BMD and could be additive use for prevention of bone loss in hyperlipidemia patients.
|
Authors | Somlak Chuengsamarn, Suthee Rattanamongkoulgul, Somponge Suwanwalaikorn, Somkiat Wattanasirichaigoon, Larry Kaufman |
Journal | Bone
(Bone)
Vol. 46
Issue 4
Pg. 1011-5
(Apr 2010)
ISSN: 1873-2763 [Electronic] United States |
PMID | 20045497
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010 Elsevier Inc. All rights reserved. |
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
- Simvastatin
- Gemfibrozil
|
Topics |
- Aged
- Bone Density
(drug effects)
- Bone Diseases, Metabolic
(complications, drug therapy)
- Female
- Gemfibrozil
(therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hyperlipidemias
(complications, drug therapy)
- Hypolipidemic Agents
(therapeutic use)
- Male
- Middle Aged
- Osteogenesis
(drug effects)
- Patient Selection
- Prospective Studies
- Simvastatin
(therapeutic use)
- Treatment Outcome
|